Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $2.18 per share in its upcoming report, which indicates a year-over-year increase of 3.8%. Revenues are expected to be $15.78 billion, up 6% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Astrazeneca metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Alliance Revenue- Total' will likely reach $875.42 million. The estimate suggests a change of +22.6% year over year.
The average prediction of analysts places 'Collaboration Revenue- Total' at $173.65 million. The estimate indicates a change of -78.7% from the prior-year quarter.
The consensus estimate for 'BioPharmaceuticals- V&I- Synagis- Established RoW' stands at $38.47 million. The estimate points to a change of +28.2% from the year-ago quarter.
Analysts' assessment points toward 'BioPharmaceuticals- R&I- Symbicort- World' reaching $695.87 million. The estimate indicates a change of +1.7% from the prior-year quarter.
The consensus among analysts is that 'BioPharmaceuticals- V&I- U.S.' will reach $117.31 million. The estimate indicates a year-over-year change of +46.6%.
It is projected by analysts that the 'BioPharmaceuticals- R&I- Symbicort- U.S.' will reach $309.80 million. The estimate indicates a change of +3.6% from the prior-year quarter.
According to the collective judgment of analysts, 'BioPharmaceuticals- CVRM- Crestor- U.S.' should come in at $10.74 million. The estimate points to a change of -17.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Oncology- Tagrisso- U.S.' of $859.75 million. The estimate indicates a year-over-year change of +12.1%.
Analysts forecast 'BioPharmaceuticals- R&I- Fasenra- U.S.' to reach $339.58 million. The estimate points to a change of +13.6% from the year-ago quarter.
Analysts predict that the 'BioPharmaceuticals- CVRM- Brilinta- U.S.' will reach $64.66 million. The estimate indicates a year-over-year change of -68.9%.
Analysts expect 'Oncology- Lynparza- U.S.' to come in at $394.55 million. The estimate indicates a change of +4.4% from the prior-year quarter.
Based on the collective assessment of analysts, 'Oncology- Imfinzi- U.S.' should arrive at $964.07 million. The estimate indicates a year-over-year change of +33.7%.
View all Key Company Metrics for Astrazeneca here>>>
Shares of Astrazeneca have experienced a change of -1.5% in the past month compared to the +0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), AZN is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
